This study investigates differences in μ-opioid receptor mediated neurotransmission in healthy controls and overnight-abstinent smokers, and potential effects of the OPRM1 A118G genotype. It also examines the effects of smoking denicotinized (DN) and average nicotine (N) cigarettes on the μ-opioid system. Positron emission tomography with (11)C-carfentanil was used to determine regional brain μ-opioid receptor (MOR) availability (non-displaceable binding potential, BPND) in a sample of 19 male smokers and 22 nonsmoking control subjects. Nonsmokers showed greater MOR BPND than overnight abstinent smokers in the basal ganglia and thalamus. BPND in the basal ganglia was negatively correlated with baseline craving levels and Fagerström scores. Interactions between group and genotype were seen in the nucleus accumbens bilaterally and the amygdala, with G-allele carriers demonstrating lower BPND in these regions, but only among smokers. After smoking the DN cigarette, smokers showed evidence of MOR activation in the thalamus and nucleus accumbens. No additional activation was observed after the N cigarette, with a mean effect of increases in MOR BPND (i.e., deactivation) with respect to the DN cigarette effects in the thalamus and left amygdala. Changes in MOR BPND were related to both Fagerström scores and changes in craving. This study showed that overnight-abstinent smokers have lower concentrations of available MORs than controls, an effect that was related to both craving and the severity of addiction. It also suggests that nicotine non-specific elements of the smoking experience have an important role in regulating MOR-mediated neurotransmission, and in turn modulating withdrawal-induced craving ratings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891463 | PMC |
| http://dx.doi.org/10.1016/j.pnpbp.2016.04.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigation of [C]carfentanil for mu opioid receptor quantification in the rat brain.
Sci Rep
July 2024
Laboratory of Neuroimaging, National Institute On Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, 20892, USA.
Article Synopsis
- Carfentanil ([C]CFN) is the only carbon-11 labeled radiotracer used for PET imaging of mu opioid receptors, but its effects in preclinical studies haven't been fully explored.
- In studies with anesthetized rats, researchers found that higher doses of CFN led to significant changes in vital signs and a correlation between CFN mass and mu opioid receptor availability in the brain.
- The results suggest that controlling CFN dosage is crucial to avoid complications and accurately measure mu opioid receptor activity, highlighting the need for careful quality control in PET studies with this radiotracer.
Unique and joint associations of polygenic risk for major depression and opioid use disorder with endogenous opioid system function.
Neuropsychopharmacology
September 2022
Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania and Mental Illness Research, Education and Clinical Center, Crescenz VAMC, Philadelphia, PA, 19104, USA.
Article Synopsis
- Major depressive disorder (MDD) and opioid use disorder (OUD) are common genetic disorders that often occur together and can be fatal.
- A study with 144 healthy participants examined the relationship between genetic risk for these disorders and the behavior of the µ-opioid receptor (MOR) under stress.
- Findings showed that MDD and OUD genetic risks were linked to how the opioid system activates during stress, particularly in females, indicating a potential pathway for combined treatment approaches.
Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission.
Mol Psychiatry
February 2022
Department of Psychiatry, John T Mather Memorial Hospital, Northwell Health, Port Jefferson, NY, USA.
Behavioral conditioning and expectation can have profound impact on animal and human physiology. Placebo, administered under positive expectation in clinical trials, can have potent effects on disease pathology, obscuring active medications. Emerging evidence suggests placebo-responsive neurotransmitter systems (e.
View Article and Find Full Text PDFAcute acetate administration increases endogenous opioid levels in the human brain: A [C]carfentanil molecular imaging study.
J Psychopharmacol
May 2021
Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, UK.
Introduction: A recent study has shown that acetate administration leads to a fourfold increase in the transcription of proopiomelanocortin (POMC) mRNA in the hypothalamus. POMC is cleaved to peptides, including β-endorphin, an endogenous opioid (EO) agonist that binds preferentially to the µ-opioid receptor (MOR). We hypothesised that an acetate challenge would increase the levels of EO in the human brain.
View Article and Find Full Text PDFPharmacological Characterization of Low-to-Moderate Affinity Opioid Receptor Agonists and Brain Imaging with F-Labeled Derivatives in Rats.
J Med Chem
September 2020
Realomics SRI, Kjemisk Institutt, Universitetet i Oslo, N-0376 Oslo, Norway.
The 3,4-dichloro--(1-(dimethylamino)cyclohexyl)methyl benzamide scaffold was studied as a template for F-positron emission tomography (F-PET) radiotracer development emphasizing sensitivity to changes in opioid receptor (OR) occupancy over high affinity. Agonist potency, binding affinity, and relevant pharmacological parameters of 15 candidates were investigated. Two promising compounds and with μ-OR (MOR) selective agonist activity in the moderate range (EC = 1-100 nM) were subjected to F-fluorination, autoradiography, and small-animal PET imaging.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!